May 19, 2020 / 11:30AM GMT
Michael Leuchten - UBS Investment Bank, Research Division - Co-Head of Pharmaceuticals Research of Equity Research
Good morning, good afternoon, everybody. My name is Michael Leuchten. I'm one of the pharma analysts at UBS based in London. It's my pleasure today to introduce the Bayer team for today's -- for today's fireside chat, we have Jörgen Möller who's -- so Jörg Möller who's the Head of R&D at Bayer pharma, and we also have Jürgen Beunink with us from the IR team.
For participants on today's presentation, there is a way of submitting questions to me. I will see them on my screen. If you want to do that, please do so. We will have a start off with a list of questions that I will go through with Jörg, and then we'll see how far we can go and we can maybe fill some questions after.
So with that, thank you very much for joining us today.
Questions and Answers:
Michael Leuchten - UBS Investment Bank, Research Division - Co-Head of Pharmaceuticals Research of Equity ResearchMaybe to start off with, obviously, the COVID